NO2016017I1 - Sekukinumab - Google Patents

Sekukinumab

Info

Publication number
NO2016017I1
NO2016017I1 NO2016017C NO2016017C NO2016017I1 NO 2016017 I1 NO2016017 I1 NO 2016017I1 NO 2016017 C NO2016017 C NO 2016017C NO 2016017 C NO2016017 C NO 2016017C NO 2016017 I1 NO2016017 I1 NO 2016017I1
Authority
NO
Norway
Prior art keywords
sekukinumab
Prior art date
Application number
NO2016017C
Other languages
English (en)
Original Assignee
Novartis Ag
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32982602&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2016017(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO2016017I1 publication Critical patent/NO2016017I1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents; Non-steroidal anti-inflammatory drugs (NSAIDs)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
NO2016017C 2016-08-23 Sekukinumab NO2016017I1 (no)

Publications (1)

Publication Number Publication Date
NO2016017I1 true NO2016017I1 (no) 2016-08-23

Family

ID=32982602

Family Applications (8)

Application Number Title Priority Date Filing Date
NO20070985A NO336279B1 (no) 2004-08-05 2007-02-20 IL-17 bindende antistoff, farmasøytisk sammensetning og kit omfattende slike antistoff, samt DNA konstruksjon som koder for slike IL-17 bindende antistoff og ekspresjonsvektor.
NO20150064A NO337286B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av ankyloserende spondylitt
NO20150065A NO337129B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av psoriasis artritt
NO2015023C NO2015023I1 (no) 2004-08-05 2015-10-26 Sekukinumab
NO20151787A NO341384B1 (no) 2004-08-05 2015-12-23 IL-17 bindende antistoff for anvendelse ved behandling av inflammatorisk artritt og anvendelse av det IL-17 bindende antistoff for fremstilling av medikament for behandling av ankyloserende spondylitt.
NO2016017C NO2016017I1 (no) 2016-08-23 Sekukinumab
NO20171697A NO20171697A1 (no) 2004-08-05 2017-10-24 IL-17 Antagonistiske antistoffer
NO2018007C NO2018007I1 (no) 2004-08-05 2018-02-14 sekukinumab

Family Applications Before (5)

Application Number Title Priority Date Filing Date
NO20070985A NO336279B1 (no) 2004-08-05 2007-02-20 IL-17 bindende antistoff, farmasøytisk sammensetning og kit omfattende slike antistoff, samt DNA konstruksjon som koder for slike IL-17 bindende antistoff og ekspresjonsvektor.
NO20150064A NO337286B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av ankyloserende spondylitt
NO20150065A NO337129B1 (no) 2004-08-05 2015-01-13 IL-17 bindende antistoff for anvendelse ved behandling av psoriasis artritt
NO2015023C NO2015023I1 (no) 2004-08-05 2015-10-26 Sekukinumab
NO20151787A NO341384B1 (no) 2004-08-05 2015-12-23 IL-17 bindende antistoff for anvendelse ved behandling av inflammatorisk artritt og anvendelse av det IL-17 bindende antistoff for fremstilling av medikament for behandling av ankyloserende spondylitt.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20171697A NO20171697A1 (no) 2004-08-05 2017-10-24 IL-17 Antagonistiske antistoffer
NO2018007C NO2018007I1 (no) 2004-08-05 2018-02-14 sekukinumab

Country Status (38)

Country Link
US (7) US7807155B2 (no)
EP (5) EP2902039B1 (no)
JP (1) JP4682200B2 (no)
KR (2) KR20080029018A (no)
CN (1) CN101001645B (no)
AR (1) AR050200A1 (no)
AT (1) AT517924T (no)
AU (2) AU2005268857C1 (no)
BR (1) BRPI0513078B8 (no)
CA (1) CA2573586C (no)
CY (4) CY1111963T1 (no)
DK (4) DK2366405T3 (no)
EC (1) ECSP077198A (no)
ES (4) ES2536228T3 (no)
GB (1) GB0417487D0 (no)
HK (3) HK1101277A1 (no)
HR (3) HRP20110758T4 (no)
HU (4) HUE025815T2 (no)
IL (1) IL180717A (no)
LT (3) LT2902039T (no)
LU (2) LU92768I2 (no)
MA (1) MA28982B1 (no)
MX (1) MX2007001338A (no)
MY (1) MY144925A (no)
NL (1) NL300749I2 (no)
NO (8) NO336279B1 (no)
NZ (1) NZ552658A (no)
PE (1) PE20060418A1 (no)
PL (4) PL2902039T3 (no)
PT (4) PT2364729E (no)
RU (2) RU2426741C3 (no)
SG (1) SG155186A1 (no)
SI (4) SI2902039T1 (no)
TN (1) TNSN07034A1 (no)
TR (1) TR201808057T4 (no)
TW (1) TWI359153B (no)
WO (1) WO2006013107A1 (no)
ZA (1) ZA200700242B (no)

Families Citing this family (127)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co ANTIBODIES DIRECTED TO M-CSF
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) * 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
EP2322219A3 (en) * 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease
KR101158959B1 (ko) 2005-12-13 2012-07-09 일라이 릴리 앤드 캄파니 항-il-17 항체
RU2456298C2 (ru) 2005-12-20 2012-07-20 ЭсБиАй БАЙОТЕК КО., ЛТД. Антитело против ilt17
AR060017A1 (es) 2006-01-13 2008-05-21 Novartis Ag Composiciones y metodos de uso para anticuerpos de dickkopf -1
KR20080099290A (ko) * 2006-01-31 2008-11-12 노파르티스 아게 암 치료용 il-17 길항 항체
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
TW200815469A (en) * 2006-06-23 2008-04-01 Astrazeneca Ab Compounds
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CN101646690B (zh) 2006-08-11 2013-10-23 默沙东公司 抗il-17a抗体
GB0620729D0 (en) 2006-10-18 2006-11-29 Ucb Sa Biological products
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Il-23拮抗劑於治療感染之用途
EP2425838A3 (en) 2007-02-28 2012-05-02 Schering Corporation Combination therapy for treatment of immune disorders
KR20160017119A (ko) 2007-05-29 2016-02-15 노파르티스 아게 항-il-1-베타 치료법에 대한 신규 적응증
CN101932935A (zh) * 2007-06-20 2010-12-29 先灵公司 用于炎性关节病抗白介素-17a治疗的关节破坏生物标记
WO2009015063A2 (en) * 2007-07-23 2009-01-29 Centocor Methods and compositions for treating fibrosis related disorders using il-17 antagonists
US20110195509A1 (en) * 2007-09-06 2011-08-11 Drew Pardoll Treatment of th17-mediated autoimmune disease via inhibition of stat 3
WO2009072802A2 (en) * 2007-12-03 2009-06-11 Amorepacific Corporation Composition for slimming
WO2009082624A2 (en) * 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
JP5886523B2 (ja) * 2008-01-09 2016-03-16 ザ スキーペンズ アイ リサーチ インスティチュート インコーポレイテッド 眼の炎症性障害を処置するための治療組成物
GB0807413D0 (en) 2008-04-23 2008-05-28 Ucb Pharma Sa Biological products
EA024654B1 (ru) * 2008-04-29 2016-10-31 Эмджен Рисерч (Мьюник) Гмбх Ингибиторы гранулоцитарно-макрофагального колониестимулирующего фактора (gm-csf) и интерлейкина-17 (il-17) для терапии
JP5646457B2 (ja) 2008-04-29 2014-12-24 アッヴィ・インコーポレイテッド 二重可変ドメイン免疫グロブリン及びその使用
CA2721713C (en) 2008-05-05 2019-07-09 Novimmune Sa Anti-il-17a/il-17f cross-reactive antibodies and methods of use thereof
CN102112494A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
CN102112495A (zh) 2008-06-03 2011-06-29 雅培制药有限公司 双重可变结构域免疫球蛋白及其用途
CA2729949A1 (en) 2008-07-08 2010-01-14 Abbott Laboratories Prostaglandin e2 dual variable domain immunoglobulins and uses thereof
AU2009296299A1 (en) 2008-09-29 2010-04-01 Roche Glycart Ag Antibodies against human IL 17 and uses thereof
RU2015132478A (ru) 2009-03-05 2015-12-10 Эббви Инк. Связывающие il-17 белки
HUE035240T2 (hu) * 2009-04-27 2018-05-02 Novartis Ag Preparations and methods for increasing muscle strength
WO2010128407A2 (en) 2009-05-05 2010-11-11 Novimmune S.A. Anti-il-17f antibodies and methods of use thereof
NZ598929A (en) 2009-09-01 2014-05-30 Abbvie Inc Dual variable domain immunoglobulins and uses thereof
JP2013507132A (ja) * 2009-10-10 2013-03-04 ザ ボード オブ トラスティーズ オブ ザ リーランド スタンフォード ジュニア ユニバーシティ Il−17ファミリーサイトカイン組成物及び使用
BR112012008833A2 (pt) 2009-10-15 2015-09-08 Abbott Lab imunoglobulinas de dominio variavel duplo e usos das mesmas
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
ES2728115T3 (es) 2009-10-30 2019-10-22 Janssen Biotech Inc IL-17A antagonists
CN102906118B (zh) 2010-05-20 2017-07-28 埃博灵克斯股份有限公司 与her3相关的生物材料
MX341579B (es) 2010-08-03 2016-08-25 Abbvie Inc * IMMUNOGLOBULINAS OF DOUBLE VARIABLE DOMAIN AND USES OF THE SAME.
JP2013537414A (ja) * 2010-08-05 2013-10-03 アナプティスバイオ インコーポレイティッド Il−17に対する抗体
EP3578205A1 (en) 2010-08-06 2019-12-11 ModernaTX, Inc. A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof
TW201211252A (en) 2010-08-26 2012-03-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
CN103429606A (zh) 2010-10-01 2013-12-04 现代治疗公司 设计核酸及其使用方法
SG188979A1 (en) * 2010-10-08 2013-05-31 Novartis Ag Methods of treating psoriasis using il-17 antagonists
AU2014259523B2 (en) * 2010-11-05 2016-02-04 Novartis Ag Methods of treating psoriatic arthritis using IL-17 antagonists
TR201909531T4 (tr) * 2010-11-05 2019-07-22 Novartis Ag Anti-il-17 anti̇korlari kullanilarak anki̇lozan spondi̇li̇t tedavi̇ etme yöntemleri̇
TW201307845A (zh) 2010-12-13 2013-02-16 Novartis Ag 預測方法及利用il-17拮抗劑治療關節炎的方法
JP5947041B2 (ja) * 2011-01-07 2016-07-06 第一三共ヘルスケア株式会社 安全なil−17産生抑制剤
GB201100282D0 (en) 2011-01-07 2011-02-23 Ucb Pharma Sa Biological methods
US10208349B2 (en) 2011-01-07 2019-02-19 Ucb Biopharma Sprl Lipocalin 2 as a biomarker for IL-17 inhibitor therapy efficacy
US20140004540A1 (en) * 2011-01-13 2014-01-02 Universite Paris Descartes Methods and kits for predicting the risk of having a cardiovascular event in a subject
RS56298B1 (sr) 2011-01-14 2017-12-29 Ucb Biopharma Sprl Antitelo koje vezuje il-17a i il-17f
WO2012125680A1 (en) 2011-03-16 2012-09-20 Novartis Ag Methods of treating vasculitis using an il-17 binding molecule
CA2831787A1 (en) 2011-03-29 2012-10-04 Glaxosmithkline Llc Buffer system for protein purification
WO2012135805A2 (en) 2011-03-31 2012-10-04 modeRNA Therapeutics Delivery and formulation of engineered nucleic acids
HUE037225T2 (hu) 2011-05-05 2018-08-28 Merck Patent Gmbh Amino acid sequences directed against IL-17A, IL-17F and / or IL17-A / F and polypeptides containing them
US9464124B2 (en) 2011-09-12 2016-10-11 Moderna Therapeutics, Inc. Engineered nucleic acids and methods of use thereof
EP3492109B1 (en) 2011-10-03 2020-03-04 ModernaTX, Inc. Modified nucleosides, nucleotides, and nucleic acids, and uses thereof
CA2856252A1 (en) 2011-11-21 2013-05-30 Novartis Ag Methods of treating psoriatic arthritis (psa) using il-17 antagonists and psa response or non-response alleles
WO2013082282A1 (en) 2011-12-02 2013-06-06 lNOVARTIS AG Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease.
US20130156849A1 (en) 2011-12-16 2013-06-20 modeRNA Therapeutics Modified nucleoside, nucleotide, and nucleic acid compositions
US9283287B2 (en) 2012-04-02 2016-03-15 Moderna Therapeutics, Inc. Modified polynucleotides for the production of nuclear proteins
WO2013087912A1 (en) 2011-12-16 2013-06-20 Synthon Biopharmaceuticals B.V. Compounds and methods for treating inflammatory diseases
UY34558A (es) 2011-12-30 2013-07-31 Abbvie Inc DUAL SPECIFIC UNION PROTEINS DIRECTED AGAINST IL-13 AND / OR IL-17
EP2809660B1 (en) 2012-02-02 2016-01-20 Ensemble Therapeutics Corporation Macrocyclic compounds for modulating il-17
US10501512B2 (en) 2012-03-30 2019-12-10 Modernatx, Inc. Modified polynucleotides
AU2013243950A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9572897B2 (en) 2012-04-02 2017-02-21 Modernatx, Inc. Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins
MX2014011818A (es) 2012-04-05 2014-12-10 Hoffmann La Roche BISPECIFIC ANTIBODIES AGAINST THE WEAK INDUCTOR OF THE HUMAN TNF (TWEAK) APPLICATION RELATED TO HUMAN IL17 AND USES OF THE SAME.
US20150125462A1 (en) 2012-04-20 2015-05-07 Stephan Bek Methods of treating ankylosing spondylitis using il-17 antagonists
US8945553B2 (en) 2012-05-22 2015-02-03 Bristol-Myers Squibb Company Bispecific antibodies to IL-23 and IL-17A/F
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US9163093B2 (en) 2012-11-01 2015-10-20 Abbvie Inc. Anti-DLL4/VEGF dual variable domain immunoglobulin and uses thereof
US9597380B2 (en) 2012-11-26 2017-03-21 Modernatx, Inc. Terminally modified RNA
WO2014107737A2 (en) 2013-01-07 2014-07-10 Eleven Biotherapeutics, Inc. Local delivery of il-17 inhibitors for treating ocular disease
CU24300B1 (es) 2013-02-08 2017-12-08 Novartis Ag Anticuerpos anti-il-17a útiles en el tratamiento de trastornos autoinmunes e inflamatorios
WO2014144280A2 (en) 2013-03-15 2014-09-18 Abbvie Inc. DUAL SPECIFIC BINDING PROTEINS DIRECTED AGAINST IL-1β AND / OR IL-17
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
WO2014155278A2 (en) * 2013-03-26 2014-10-02 Novartis Ag Methods of treating autoimmune diseases using il-17 antagonists
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
US9707154B2 (en) 2013-04-24 2017-07-18 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
US9603882B2 (en) 2013-08-13 2017-03-28 Industrial Technology Research Institute Method for modulating Th17 cells and method for treating a disease related to modulation of Th17 cells
EP3033107A1 (en) 2013-08-15 2016-06-22 Novartis AG Methods of treating generalized pustular psoriasis (gpp) using il-17 antagonists
AU2014314053B2 (en) 2013-08-30 2020-03-12 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
US10023626B2 (en) 2013-09-30 2018-07-17 Modernatx, Inc. Polynucleotides encoding immune modulating polypeptides
EP3052521A1 (en) 2013-10-03 2016-08-10 Moderna Therapeutics, Inc. Polynucleotides encoding low density lipoprotein receptor
WO2015070697A1 (zh) 2013-11-18 2015-05-21 上海恒瑞医药有限公司 Il-17a结合物及其用途
WO2015113494A1 (zh) * 2014-01-28 2015-08-06 北京韩美药品有限公司 双功能融合蛋白及其制备方法和用途
WO2015200165A1 (en) 2014-06-23 2015-12-30 Janssen Biotech, Inc. Interferon alpha and omega antibody antagonists
EP3191120A1 (en) 2014-09-10 2017-07-19 Novartis Ag Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients
RU2609627C2 (ru) * 2014-09-26 2017-02-02 Закрытое Акционерное Общество "Биокад" Высокоаффинные и агрегационно стабильные антитела на основе вариабельных доменов vl и производного vhh
MX2017004669A (es) 2014-10-08 2017-06-19 Novartis Ag Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer.
CA2964367A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
US10093733B2 (en) 2014-12-11 2018-10-09 Abbvie Inc. LRP-8 binding dual variable domain immunoglobulin proteins
AR103172A1 (es) * 2014-12-22 2017-04-19 Novartis Ag SELECTIVE REDUCTION OF CYSTEINE WASTE IN ANTIBODIES IL-17
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag PHARMACEUTICAL PRODUCTS AND STABLE LIQUID COMPOSITIONS OF ANTIBODIES IL-17
KR20170116023A (ko) 2015-01-12 2017-10-18 애피바디 에이비 Il-17a-결합 폴리펩티드
JP2018506275A (ja) 2015-01-28 2018-03-08 ジェネンテック, インコーポレイテッド 多発性硬化症の遺伝子発現マーカー及び治療
CN108251431B (zh) 2015-03-05 2020-12-08 北京百特美博生物科技有限公司 双载体系统及其用途
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗vegf、pdgf及/或其受體之結合蛋白
EP3322725A1 (en) 2015-07-16 2018-05-23 Eli Lilly and Company Treatment of pruritus
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
WO2017019894A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to lag-3
EP3365011A1 (en) 2015-10-19 2018-08-29 Novartis AG Methods of treating non-radiographic axial spondyloarthritis using interleukin-17 (il-17) antagonists
BR112018012138A2 (pt) 2015-12-17 2018-12-04 Novartis Ag moléculas de anticorpo para pd-1 e usos das mesmas
BR112018067813A2 (pt) 2016-03-10 2019-01-15 Acceleron Pharma Inc proteínas de ligação ao receptor de activina tipo 2 e usos do mesmo
CN107488227A (zh) * 2016-06-12 2017-12-19 三生国健药业(上海)股份有限公司 抗人白细胞介素‑17a单克隆抗体、其制备方法和应用
WO2017221174A1 (en) 2016-06-22 2017-12-28 Novartis Ag Methods of treating vitiligo using interleukin-17 (il-17) antibodies
US20190194311A1 (en) 2016-07-19 2019-06-27 Novartis Ag Methods of treating new-onset plaque type psoriasis using il-17 antagonists
JP2019505516A (ja) 2016-11-28 2019-02-28 ノバルティス アーゲー インターロイキン−17(il−17)アンタゴニストを使用してざ瘡を治療する方法
AR110873A1 (es) 2017-02-10 2019-05-08 Genentech Inc ANTIBODIES AGAINST TRIPTASE, COMPOSITIONS OF THESE AND USES OF THESE
WO2018158741A1 (en) 2017-03-03 2018-09-07 Novartis Ag Psoriasis disease modification following long-term treatment with an il-17 antagonist
TW201842933A (zh) 2017-05-05 2018-12-16 瑞士商諾華公司 Method for selectively treating asthma using IL-17 antagonist
CN108359011B (zh) 2017-07-21 2019-06-25 华博生物医药技术(上海)有限公司 靶向于白介素17a的抗体、其制备方法和应用
WO2019087133A1 (en) 2017-11-02 2019-05-09 Novartis Ag Method of treating tendinopathy using interleukin-17 (il-17)
US20200277369A1 (en) 2017-11-20 2020-09-03 Novartis Ag Method of treating hidradentitis suppurativa with il-17 antagonists
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 Chimeric antigen receptor targeting BCMA and use thereof
AU2019277029A1 (en) 2018-06-01 2020-11-12 Novartis Ag Binding molecules against BCMA and uses thereof
WO2020024931A1 (en) * 2018-07-31 2020-02-06 Shen Weiqun Anti-il-17a antibodies and use thereof
WO2020064702A1 (en) 2018-09-25 2020-04-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of antagonists of th17 cytokines for the treatment of bronchial remodeling in patients suffering from allergic asthma
WO2020157305A1 (en) 2019-01-31 2020-08-06 Numab Therapeutics AG Multispecific antibodies having specificity for tnfa and il-17a, antibodies targeting il-17a, and methods of use thereof
EP3689907A1 (en) 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
EP0463151B1 (en) 1990-01-12 1996-06-12 Cell Genesys, Inc. Generation of xenogeneic antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2309604C (en) 1997-11-10 2010-01-12 Cytimmune Sciences, Inc. Compositions and methods for targeted delivery of factors
US6562333B1 (en) 1993-06-14 2003-05-13 Schering Corporation Purified mammalian CTLA-8 antigens and related reagents
US6274711B1 (en) * 1993-06-14 2001-08-14 Inserm, Institut National De La Sante Et De La Recherche Medicale Purified mammalian CTLA-8 antigens and related reagents
DE69633617T3 (de) * 1995-03-23 2010-05-20 Immunex Corp., Seattle Il-17 receptor
PT839196E (pt) 1995-07-19 2005-09-30 Inst Genetics Llc Ctla-8 humana e utilizacoes de proteinas relacionadas com ctla-8
US6074849A (en) * 1995-07-19 2000-06-13 Genetics Institute, Inc. Polynucleotides encoding human CTLA-8 related proteins
AT222768T (de) 1995-10-27 2002-09-15 Schering Corp Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
AT429241T (de) 1996-11-27 2009-05-15 Immunex Corp Verfahren zur regulierung der stickstoffmonoxid- erzeugung
US6849719B2 (en) 1997-09-17 2005-02-01 Human Genome Sciences, Inc. Antibody to an IL-17 receptor like protein
US6482923B1 (en) 1997-09-17 2002-11-19 Human Genome Sciences, Inc. Interleukin 17-like receptor protein
US6635443B1 (en) 1997-09-17 2003-10-21 Human Genome Sciences, Inc. Polynucleotides encoding a novel interleukin receptor termed interleukin-17 receptor-like protein
WO1999032632A1 (en) 1997-12-19 1999-07-01 Millennium Pharmaceuticals, Inc. Novel embryo-derived interleukin related factor molecules and uses therefor
AU2031399A (en) 1998-01-09 1999-07-26 Immunex Corporation Human and murine il-17d, cytokine related to interleukin-17: dna and polypeptides
EP1045905A2 (en) 1998-01-09 2000-10-25 Immunex Corporation Il-17rh dna and polypeptides
WO1999041402A2 (en) 1998-02-11 1999-08-19 Maxygen, Inc. Targeting of genetic vaccine vectors
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
CA2706859A1 (en) 1998-09-17 2000-03-23 Zymogenetics, Inc. Mammalian transforming growth factor beta - 9
AU6277799A (en) 1998-10-02 2000-04-26 Eli Lilly And Company Il-17 homolog nucleic acids, polypeptides, vectors, host cells, methods and usesthereof
JP2000186046A (ja) * 1998-10-14 2000-07-04 Sankyo Co Ltd 慢性関節リウマチ治療剤及び診断方法
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
DE29820466U1 (de) 1998-11-16 1999-04-08 Reutter Werner Prof Dr Med Rekombinante Glycoproteine und sie enthaltende Arzneimittel
US6734172B2 (en) 1998-11-18 2004-05-11 Pacific Northwest Research Institute Surface receptor antigen vaccines
US6562578B1 (en) * 1999-01-11 2003-05-13 Schering Corporation IL-17-like cytokine binding compounds and antibodies
CN1357042A (zh) 1999-01-11 2002-07-03 先灵公司 白介素-17相关哺乳动物细胞因子、编码其的多核苷酸、应用
AR022237A1 (es) 1999-01-11 2002-09-04 Schering Corp Citoquinas mamiferas purificadas; reactivos y metodos relacionados
EP1031346B1 (en) 1999-01-27 2002-05-02 Idea Ag Noninvasive vaccination through the skin
PL200919B1 (xx) 1999-02-12 2009-02-27 Lexigen Pharm Corp Use of angiogenesis inhibiting agent and anti-tumor agent compositions, therapeutic composition for the treatment of cancer and a cancer cell treatment kit
EP1053751A1 (en) 1999-05-17 2000-11-22 Institut Curie Compositions and methods for treating cell proliferation disorders
US6036128A (en) 1999-05-17 2000-03-14 Common Ground Recycling, Inc. Tire shredding machine and method of using the same
AU6677000A (en) 1999-08-27 2001-03-26 University Health Network Method for activating cytotoxic t-lymphocytes (ctls) in vivo : composition comprising antibody anti cd40 (or cd40l or cd40 binding protein) and an antigen
JP2001086046A (ja) * 1999-09-09 2001-03-30 Nec Corp カメラ付き携帯電話装置
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Hakko Kirin Co., Ltd. Anti-cd40 monoclonal antibody
US7220840B2 (en) * 2000-06-16 2007-05-22 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to B lymphocyte stimulator protein
JP4902087B2 (ja) 2000-06-16 2012-03-21 ヒューマン ジノーム サイエンシーズ, インコーポレイテッドHuman Genome Sciences, Inc. BLySに免疫特異的に結合する抗体
US20060083713A1 (en) 2000-10-13 2006-04-20 Eli Lilly And Company Methods of using a human il-17 related polypeptide to treat disease
EP1326626B1 (en) * 2000-10-18 2020-04-01 Immunex Corporation Methods for treating rheumatoid arthritis using il-17 antagonists
AU2002326285A1 (en) 2001-01-25 2003-01-02 Zymogenetics, Inc. Method for treating psoriasis by using an il-17d antagonist
AU2002364954A1 (en) 2001-11-16 2003-07-15 Human Genome Sciences, Inc. ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS
AU2003259995B2 (en) 2002-08-28 2009-07-02 Immunex Corporation Compositions and methods for treating cardiovascular disease
AU2004270103B2 (en) * 2003-05-21 2012-02-23 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies against Bacillusanthracis protective antigen
DK1983000T3 (en) 2003-11-21 2015-12-07 Ucb Biopharma Sprl A method for the treatment of multiple sclerosis by inhibiting IL-17 activity
WO2005108616A1 (en) * 2004-05-03 2005-11-17 Schering Corporation Use of il-17 expression to predict skin inflammation; methods of treatment
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP2322219A3 (en) 2005-09-01 2013-06-05 Merck Sharp & Dohme Corp. Use of IL-23 and IL-17 antagonists to treat autoimmune ocular inflammatory disease

Also Published As

Publication number Publication date
EP2366405B1 (en) 2015-02-25
NO341384B1 (no) 2017-10-30
NO2018007I1 (no) 2018-02-14
ES2487533T3 (es) 2014-08-21
JP2008507988A (ja) 2008-03-21
AU2010201689B2 (en) 2011-09-29
DK1776142T6 (en) 2015-07-06
CY1120723T1 (el) 2019-12-11
RU2426741C3 (ru) 2017-11-15
AU2005268857B2 (en) 2010-01-28
CY1115444T1 (el) 2017-01-04
DK2902039T3 (en) 2018-07-16
ZA200700242B (en) 2008-08-27
CY1111963T1 (xx) 2015-11-04
SI2364729T1 (sl) 2014-08-29
TR201808057T4 (tr) 2018-06-21
EP2902039B1 (en) 2018-04-11
NO2015023I2 (no) 2015-10-26
HK1256639A1 (zh) 2019-09-27
ES2677245T3 (es) 2018-07-31
HRP20181069T1 (hr) 2018-09-07
EP2902039A1 (en) 2015-08-05
SI2902039T1 (en) 2018-07-31
IL180717A (en) 2012-07-31
GB0417487D0 (en) 2004-09-08
CY1116256T1 (el) 2017-02-08
PL2364729T3 (pl) 2014-10-31
ES2367440T7 (es) 2015-07-14
NO20151787L (no) 2006-02-06
EP1776142B9 (en) 2016-09-07
KR20070036166A (ko) 2007-04-02
CA2573586C (en) 2013-06-25
KR100852523B1 (ko) 2008-08-14
EP2364729B1 (en) 2014-05-14
EP2364729A2 (en) 2011-09-14
TNSN07034A1 (en) 2008-06-02
PL2902039T3 (pl) 2018-09-28
HUS1500037I1 (hu) 2017-10-30
NL300749I2 (nl) 2017-11-02
NO336279B1 (no) 2015-07-06
CA2573586A1 (en) 2006-02-09
US20140079719A1 (en) 2014-03-20
WO2006013107A1 (en) 2006-02-09
US20100215666A1 (en) 2010-08-26
BRPI0513078B8 (pt) 2019-08-27
AU2005268857B8 (en) 2010-05-27
MY144925A (en) 2011-11-30
US20170355762A1 (en) 2017-12-14
PE20060418A1 (es) 2006-06-15
US8617552B2 (en) 2013-12-31
NO20171697A1 (no) 2007-03-30
US20120107325A1 (en) 2012-05-03
NO20150064L (no) 2007-03-30
NO2015023I1 (no) 2015-11-02
RU2007108067A (ru) 2008-09-10
EP3409288A1 (en) 2018-12-05
TWI359153B (en) 2012-03-01
DK2364729T3 (da) 2014-07-21
US7807155B2 (en) 2010-10-05
RU2426741C2 (ru) 2011-08-20
LTPA2018515I1 (lt) 2018-10-25
ES2487533T7 (es) 2015-07-14
LTC1776142I2 (lt) 2017-04-10
AR050200A1 (es) 2006-10-04
US20150152178A1 (en) 2015-06-04
HRP20150480T1 (xx) 2015-07-17
US9765140B2 (en) 2017-09-19
ES2536228T3 (es) 2015-05-21
SI1776142T1 (sl) 2011-11-30
IL180717D0 (en) 2007-06-03
TW200617025A (en) 2006-06-01
EP2364729B3 (en) 2015-06-24
MA28982B1 (fr) 2007-11-01
HUE038187T2 (hu) 2018-10-29
KR20080029018A (ko) 2008-04-02
NO20070985L (no) 2007-03-30
DK2364729T6 (en) 2015-07-06
MX2007001338A (es) 2008-03-11
HRP20110758T1 (xx) 2011-11-30
CN101001645A (zh) 2007-07-18
PL1776142T6 (pl) 2016-06-30
PL2366405T3 (pl) 2015-08-31
EP1776142B1 (en) 2011-07-27
SG155186A1 (en) 2009-09-30
AU2005268857C1 (en) 2012-01-19
NO20150065L (no) 2007-03-30
DK1776142T3 (da) 2011-10-31
EP1776142B3 (en) 2015-06-24
EP2366405A3 (en) 2012-01-18
PT2364729E (pt) 2014-09-01
RU2011113153A (ru) 2012-10-20
LU92768I2 (en) 2015-11-03
DK2366405T3 (en) 2015-05-11
AT517924T (de) 2011-08-15
JP4682200B2 (ja) 2011-05-11
EP2366405A2 (en) 2011-09-21
US20090280131A1 (en) 2009-11-12
US8119131B2 (en) 2012-02-21
ES2367440T3 (es) 2011-11-03
AU2005268857A1 (en) 2006-02-09
US10344084B2 (en) 2019-07-09
CN101001645B (zh) 2012-09-05
NO337286B1 (no) 2016-02-29
ECSP077198A (es) 2007-02-28
US20190270804A1 (en) 2019-09-05
NO337129B1 (no) 2016-01-25
HRP20110758T4 (en) 2015-07-31
PT1776142E (pt) 2011-10-06
HK1207559A1 (en) 2016-02-05
EP2364729A3 (en) 2012-01-18
LT2902039T (lt) 2018-06-25
SI2366405T1 (sl) 2015-07-31
LUC00088I2 (no) 2018-12-17
HUE025815T2 (en) 2016-04-28
PL2364729T6 (pl) 2016-06-30
BRPI0513078A (pt) 2008-04-22
PL1776142T3 (pl) 2011-12-30
PL1776142T4 (pl) 2018-04-30
PT2366405E (pt) 2015-06-30
PT2902039T (pt) 2018-07-17
HUS1800040I1 (hu) 2018-11-28
AU2010201689A1 (en) 2010-05-20
EP1776142A1 (en) 2007-04-25
HK1101277A1 (en) 2007-10-12
NZ552658A (en) 2009-11-27
BRPI0513078B1 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
CL2015003730S1 (es) Automóvil
UY4489S (es) Auriculares
CL2017001251S1 (es) Llanta
CL2015003114S1 (es) Automovil
CL2016003106S1 (es) Llanta
CL2017001302S1 (es) Llanta
CL2016002472S1 (es) Automóvil
NO2016017I1 (no) Sekukinumab
NO2016015I1 (no) Alirokumab
CL2015002393S1 (es) Automóvil
NO2015014I2 (no) Paritaprevir
CL2017001762S1 (es) Cámara
CL2015003626S1 (es) Automóvil
CL2016000116S1 (es) Automóvil
CL2016002093S1 (es) Automovil
CL2016000247S1 (es) Automovil
CL2016000302S1 (es) Neumatico
CL2015002838S1 (es) Lapiz
CL2015001896S1 (es) Vehiculo
CL2016001960S1 (es) Automovil
UY4562S (es) Cámara
CL2016000675S1 (es) Automóvil
CL2017001250S1 (es) Llanta
CL2015003383S1 (es) Automóvil
CL2015003155S1 (es) Automóvil